HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

AuthorsSattva S Neelapu, Caron A Jacobson, Olalekan O Oluwole, Javier Munoz, Abhinav Deol, David B Miklos, Nancy L Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J Kim, Lianqing Zheng, John M Rossi, Frederick L Locke
JournalBlood (Blood) Vol. 135 Issue 23 Pg. 2106-2109 (06 04 2020) ISSN: 1528-0020 [Electronic] United States
PMID32181801 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Letter, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD19
  • Biological Products
  • axicabtagene ciloleucel
Topics
  • Adult
  • Aged
  • Antigens, CD19 (therapeutic use)
  • Biological Products
  • Female
  • Follow-Up Studies
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse (immunology, pathology, therapy)
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (immunology, pathology, therapy)
  • Prognosis
  • Survival Rate
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: